|
May 14
|
Immunome, Inc. (IMNM) Reports Q1 Loss, Misses Revenue Estimates
|
|
May 14
|
Immunome Reports First Quarter 2024 Financial Results and Provides Business Update
|
|
May 8
|
Immunome to Present at 2024 Bank of America Healthcare Conference
|
|
May 2
|
Immunome Appoints Kinney Horn as Chief Business Officer
|
|
Apr 26
|
Analysts Estimate Immunome, Inc. (IMNM) to Report a Decline in Earnings: What to Look Out for
|
|
Apr 25
|
Immunome Appoints Sandra M. Swain to Board of Directors
|
|
Apr 5
|
Immunome to Present Preclinical Data for IM-3050, Its Lead Radioligand Therapy Candidate, at 2024 American Association for Cancer Research (AACR) Annual Meeting
|
|
Apr 4
|
New Strong Sell Stocks for April 4th
|
|
Mar 28
|
Immunome Reports Full Year 2023 Financial Results and Provides Update on Recently Acquired Assets
|
|
Mar 26
|
Immunome Completes Acquisition of AL102, a Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala
|
|
Mar 26
|
Ayala Pharmaceuticals Announces Completion of Sale of AL102 to Immunome
|
|
Mar 22
|
Immunome, Inc. (NASDAQ:IMNM) surges 7.6%; individual investors who own 42% shares profited along with institutions
|
|
Mar 7
|
Immunome to Participate in the Leerink Partners Global Biopharma Conference
|
|
Mar 1
|
Immunome to Participate in the TD Cowen 44th Annual Healthcare Conference
|
|
Feb 16
|
Immunome Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
|
|
Feb 14
|
Immunome Announces Pricing of Public Offering of Common Stock
|
|
Feb 13
|
Immunome Announces Proposed Public Offering of Common Stock
|
|
Feb 10
|
Insiders See US$1.25m Investment In Immunome Jump Last Week
|
|
Feb 7
|
Immunome (IMNM) to Acquire Desmoid Tumor Candidate, Stock Up
|
|
Feb 6
|
Immunome to Acquire AL102, a Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala Pharmaceuticals
|